Related Experiment Videos
The desferrithiocin pharmacophore
R J Bergeron1, C Z Liu, J S McManis
1Department of Medicinal Chemistry, University of Florida, Gainesville 32610.
Journal of Medicinal Chemistry
|May 13, 1994
Summary
Researchers explored the (S)-desferrithiocin (DFT) structure for oral iron chelators. Modifications like thiazolidine or thiazine rings reduced activity, but N-methylhydroxamate and dihydroxamate derivatives showed efficacy for iron clearance.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Organic Chemistry
Background:
- The (S)-desferrithiocin (DFT) scaffold is a promising pharmacophore for developing orally active iron chelators.
- Understanding structure-activity relationships is crucial for optimizing drug efficacy.
Purpose of the Study:
- To identify key structural components of the desferrithiocin siderophore required for oral iron chelation.
- To evaluate the impact of specific chemical modifications on the iron-chelating activity of DFT derivatives.
Main Methods:
- Systematic chemical modification of the (S)-desferrithiocin core structure.
- Assessment of iron-chelating activity of synthesized derivatives following oral administration.
Main Results:
- Reduction to a thiazolidine or expansion to a thiazine resulted in significant loss of activity.
- Substitution of the thiazoline sulfur with oxygen also diminished activity.
- Conversion to N-methylhydroxamate and hexacoordinate dihydroxamate ligands yielded active compounds.
Conclusions:
- The N-methylhydroxamate and dihydroxamate functionalities are essential for oral iron clearance activity.
- The desferrithiocin platform serves as a valuable vector for designing novel iron chelators.
- This study elucidates critical structural requirements for orally administered siderophore-based iron chelators.